newsfilter
← Latest News
PR Newswire·

BioArctic and Mesenkia enter oncology research collaboration

  • BioArctic AB & Mesenkia Therapeutics signed a research collaboration agreement on August 19, 2026, to explore a novel antibody-based approach for glioblastoma.
  • The project combines BioArctic's BrainTransporter™ technology with an antibody developed using Mesenkia's KITAIbodies® platform.
  • The targeted antibody binds to HVEM, a protein on glioblastoma tumor cells & tumor stem cells linked to recurrence & treatment resistance.
  • BioArctic will generate the novel drug candidate & both companies will conduct preclinical studies to validate the concept before deciding on next steps.
  • The collaboration expands BioArctic's BrainTransporter pipeline into oncology & validates the platform beyond neurodegenerative diseases.
  • Gunilla Osswald, CEO of BioArctic, stated the partnership aims to target key disease mechanisms to address the high unmet need in glioblastoma treatment.
  • Moa Fransson, CEO of Mesenkia, emphasized the strategy addresses the challenge of delivering medicines to brain tumor cells to enable better treatment options.
  • Mesenkia is a pre-clinical company founded on science from Uppsala University & the University of Tokyo, focusing on glioblastoma therapeutics.
  • BioArctic is a Swedish biopharma company known for inventing Leqembi® for Alzheimer's disease & utilizing BrainTransporter™ to transport antibodies across the blood-brain barrier.